Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Abstract Text:

Dalton S McLean,Marc S Sabatine,Wei Guo,Carolyn H McCabe,Christopher P Cannon,Dalton S McLean,Marc S Sabatine,Wei Guo,Carolyn H McCabe,Christopher P Cannon,

The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction 28 (CLARITY-TIMI 28) trial was a randomized, double-blind, placebo-controlled study of clopidogrel in 3,491 patients receiving fibrinolytic therapy for ST-segment elevation myocardial infarction. Patients were randomized to clopidogrel or placebo begun at the time of fibrinolysis. This analysis reports the outcomes among the 136 patients in the trial population who underwent coronary artery bypass grafting (CABG) during the index hospitalization. There was no difference in the rates of TIMI major or minor bleeding between the clopidogrel and placebo groups from randomization to the end of follow-up (13.6% vs. 14.3%, P = 1.0) or from the time of CABG to the end of follow-up (9.1% vs. 11.4%, P = 0.78). When any day for study medication discontinuation < or = 5 days prior to CABG was chosen as a cut point to evaluate bleeding risk for clopidogrel vs. placebo, there was no excess bleeding in the clopidogrel group. Among patients undergoing CABG, there was a trend toward reduction in the risk of cardiovascular death, recurrent MI, or recurrent ischemia requiring urgent revascularization at 30 days for those taking clopidogrel (OR 0.66, 95% CI 0.27-1.5; P = 0.37), consistent with the benefit seen in the overall trial population (OR 0.80, CI 0.65-0.97; P = 0.03). In conclusion, early clopidogrel treatment among CLARITY-TIMI 28 patients undergoing CABG was not associated with an increase in the rate of peri-operative bleeding and showed a trend toward reduction in 30-day ischemic events.

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Publishing Authors By Initials

DS McLean,MS Sabatine,W Guo,CH McCabe,CP Cannon,DS McLean,MS Sabatine,W Guo,CH McCabe,CP Cannon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of thrombosis and thrombolysis

VOLUME: 24

Page Numbers: 85-91

Journal Abbreviation: J. Thromb. Thrombolysis

ISSN: 0929-5305

DAY: 24

MONTH: 02

YEAR: 2007

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502018

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.

AFFILIATION: Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Thromb Thrombolysis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28 Related Publications

• A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore.
• Amino acid residues affecting drug pump function in Candida albicans--C. albicans drug pump function.
• Analogical reasoning in working memory: resources shared among relational integration, interference resolution, and maintenance.
• Aneurysmal bone cyst of the paediatric shoulder girdle: a case series and literature review.
• Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
• Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae.
• Cognitive errors, anxiety sensitivity, and anxiety control beliefs: their unique and specific associations with childhood anxiety symptoms.
• Cortical mapping of genotype-phenotype relationships in schizophrenia.
• Current trends in computational inference from mass spectrometry-based proteomics.
• Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity.
• First recanalization of a coronary artery chronic total obstruction in an 11-year-old child with Kawasaki disease sequelae using the CROSSER catheter.
• Frances Ashcroft: 2007 Walter B. Cannon physiology in perspective lecture.
• Gender differences in aspirin use among adults with coronary heart disease in the United States.
• Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2.
• Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
• Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
• Lipid-independent Pleiotropic Effects of Statins in the Management of Acute Coronary Syndromes.
• Maintenance of AV synchrony in a small child utilizing two pacemakers and the triggered VVT mode: triggered pacing in small children.
• Mineral Trioxide Aggregate but not Light-cure Mineral Trioxide Aggregate Stimulated Mineralization.
• Predisaster trait anxiety and negative affect predict posttraumatic stress in youths after hurricane Katrina.
• Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia.
• Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential.
• Restoring federal commitment to basic nuclear medicine research.
• Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
• Self-report of attenuated psychotic experiences in a college population.
• Senate appropriators restore funding for basic nuclear medicine research at DOE.
• Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice.
• The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis.
• The course of neurocognition and social functioning in individuals at ultra high risk for psychosis.
• The relationship between performance and fMRI signal during working memory in patients with schizophrenia, unaffected co-twins, and control subjects.